Skip to main content
. 2017 Jun 2;3:14. doi: 10.1038/s41540-017-0016-1

Table 3.

Distribution of patient-level tumor response data from published clinical studies in BRAF V600E-CRC

% Change from baseline CETUX + VEMU% (N) BRAFi + MEKi% (N) EGFRi + BRAFi + MEKi% (N)
100+ 0 0 0
50:100 3.8 (1) 2.6 (1) 2.9 (1)
20:50 11.5 (3) 10.5 (4) 0
0:20 30.8 (8) 26.3 (10) 11.4 (4)
−30:0 30.8 (8) 47.4 (18) 48.6 (16)
−50:−30 7.7 (2) 10.5 (4) 20.0 (8)
−100:−30 15.4 (4) 2.6 (1) 17.1 (6)
Calculated ORR 23.1 (6/26) 13.1 (5/38) 37.1 (13/35)
Reported ORR 4 (1/27) 12 (5/43) 26 (9/35)

*EGFRi, BRAFi, and MEKi were panitumumab, dabrafenib, and trametinib. Data from refs 14, 16, 19